ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Lung Cancer

Older Early-Stage NSCLC Patients Benefit From Adjuvant Chemotherapy

Early-stage non–small-cell lung cancer patients over 70 years old derive a similar benefit as younger patients from adjuvant chemotherapy following surgical resection. Image © pruit phatsrivong / Shutterstock.com.

Lung Cancer

The combination of pemetrexed/cisplatin was superior to gemcitabine/cisplatin in non-squamous NSCLC patients negative for the thymidylate synthase enzyme.

Alectinib yielded good response rates and was very well tolerated in a phase II trial of patients with advanced, ALK-positive non–small-cell lung cancer.

In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).

A phase I study showed that transcriptional inhibitor PM01183 with doxorubicin induced responses in patients with small-cell lung cancer.

The platinum compound nedaplatin in combination with docetaxel improved outcomes over cisplatin and docetaxel in advanced squamous cell carcinoma of the lung.

Data from the LUX-Lung 8 trial showed afatinib outperformed erlotinib with regard to both progression-free and overall survival in squamous cell lung cancer.

A new agent, AZD9291, showed promising clinical activity and progression-free survival in a study of patients with advanced stage, EGFR mutation-positive NSCLC.

Pages

Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.